



The prognostic role of different renal function phenotypes in patients with acute heart failure

Alberto Palazzuoli^{a,*}, Gaetano Ruocco^a, Pierpaolo Pellicori^b, Eufemia Incampo^c, Cristina Di Tommaso^c, Roberto Favilli^c, Isabella Evangelista^a, Ranuccio Nuti^a, Jeffery M. Testani^d

^a Department of Internal Medicine, Cardiovascular Diseases Unit, University of Siena, Siena, Italy

^b Robertson Institute of Biostatistics and Clinical Trials Unit, University of Glasgow, University Avenue, Glasgow, G12 8QQ, United Kingdom of Great Britain and Northern Ireland

^c Cardiothoracic Department, Le Scotte Hospital, Siena, Italy

^d Section of Cardiovascular Medicine, Yale University School of Medicine, New Haven, CT, USA

ARTICLE INFO

Article history:

Received 16 May 2018

Received in revised form 25 October 2018

Accepted 21 November 2018

Available online 23 November 2018

Keywords:

Acute heart failure

Outcome

Renal dysfunction

Blood urea nitrogen

ABSTRACT

Objective: Worsening renal function (WRF) is common in patients treated for acute heart failure (AHF) and might be associated with a significant increase in blood nitrogen urea (BUN). Although many patients develop WRF during hospitalisation, its prognostic role is still unclear. Thus, we aimed to evaluate the prognostic relevance of WRF according to BUN changes during hospitalization.

Methods: We studied patients with AHF screened for Diur-HF Trial (NCT01441245). WRF was defined as an in-hospital rise in serum creatinine ≥ 0.3 mg/dl or estimated glomerular filtration rate (GFR) reduction $\geq 20\%$. BUN increase was defined as a rise in BUN $\geq 20\%$ during admission. Effective decongestion was defined as complete resolution of two, or more, signs of HF, or absence of clinical signs of congestion at discharge.

Results: Of 247 patients enrolled, 59 (23%) patients experienced WRF, 107 (43%) had a BUN increase $\geq 20\%$, and 111 (45%) were effectively decongested during hospitalization.

During 180 days of follow-up, 136 patients died or were re-hospitalised for AHF. An increase in BUN was an independent predictor of adverse outcome, regardless of WRF (HR = 2.19 [1.35–3.54], $p = 0.002$ and 1.71 [1.14–2.59], $p = 0.010$; with and without WRF, respectively) or congestion at discharge. WRF was not an independent predictor of outcome if BUN did not increase or when congestion was effectively relieved.

Conclusions: an increase in BUN $\geq 20\%$ during hospitalization for AHF predicts a poor outcome independently from renal function deterioration and decongestion. WRF predicts adverse outcome only if BUN increases substantially or clinical congestion persists.

© 2018 Published by Elsevier B.V.

1. Introduction

Around 50% of patients admitted with acute heart failure (AHF) will die within 5 years from diagnosis [1,2]. Thus, there is a need to identify with more precision those clinical phenotypes at higher risk of adverse outcome [3,4]. Chronic kidney disease (CKD) is one of the most potent contributing factors aggravating prognosis of patients with AHF [5]. CKD is common, and it might affect $>50\%$ of hospitalised patients with AHF, 10–15% of whom will have advanced stages of renal dysfunction [6,7]. Many studies showed that WRF during HF admission usually complicates a poorer cardiac, or renal, function and has a prognostic impact similar to that of CKD [8–10]. However, other studies did not confirm this association between WRF and prognosis: a transient WRF might

be the results of aggressive decongestion and temporary kidney overload [11–14].

Blood nitrogen urea (BUN) is not only a marker of renal function, but it also reflects neurohormonal activation, that enhances reabsorption of urea in the terminal inner medullary collecting duct [15]. Thus, changes in BUN in the context of minor fluctuation or renal function can be valuable to understand when a relative intravascular volume reduction is taking place in a patient with congestive status [16]. With the present study, we evaluate the prognostic relevance of worsening renal function and BUN changes in patients admitted with AHF.

2. Methods

2.1. Study design

This is a retrospective, post-hoc analysis of a prospective single-centre study including 247 patients admitted with AHF who were screened for the Diur-HF Trial (clinicaltrials.gov: NCT01441245) between September 2013 and July 2015.

* Corresponding author at: Department of Internal Medicine, Cardiovascular Disease Unit, Le Scotte Hospital, University of Siena, Viale Bracci, 53100 Siena, Italy.
E-mail address: palazzuoli2@unisi.it (A. Palazzuoli).

Diur-HF is an ongoing prospective, open-label, study comparing continuous with intermittent infusion of furosemide in patients admitted with a diagnosis of AHF conducted at the Departments of Internal Medicine and Cardiology of the University of Siena, Italy [17]. We screened patients over the age of 18 years admitted with dyspnoea, evidence of volume overload and/or clinical signs of HF (peripheral oedema, rales, third heart sound, jugular turgor, lung congestion on chest X-ray), in whom a diagnosis of AHF was confirmed by elevated (>100 pg/ml) levels of B-type natriuretic peptide [BNP]. Patients with end-stage (serum creatinine levels >4.0 mg/dl) renal disease or the need for renal replacement therapy (dialysis or ultrafiltration), a recent myocardial infarction (within thirty days of screening) or a systolic blood pressure <80 mm Hg were excluded. We did not screen patients with known liver or neoplastic disease or concurrent infective disease. All patients gave their written informed consent.

2.2. Clinical assessment and evaluation of congestion

Two physicians assessed patients at admission and graded congestion by giving one point for the presence of each of the following clinical signs, regardless of their severity: pulmonary crepitations, third heart sound, jugular venous distention, peripheral oedema and hepatomegaly, for a total of maximum 5 points [18]. Effective decongestion was defined as complete resolution of two, or more, clinical signs of HF, or absence of clinical signs of congestion at discharge.

2.3. Laboratory analysis

Blood tests, including creatinine, BUN and BNP were measured from blood samples taken within 24 h post-admission and prior to discharge; Renal function was monitored every 48 h. The estimated glomerular filtration rate (eGFR) was calculated using the four-variable Modification of Diet in Renal Disease (MDRD) formula [19]. CKD was defined by creatinine >1.4 mg/dl and/or eGFR <60 ml/min/1.73 m² [20]. A rise in serum creatinine ≥0.3 mg/dl or eGFR reduction ≥20% from admission to discharge were used according to conventional criteria to define WRF [21] BUN increase was defined as a rise in BUN ≥20% from admission to discharge [22].

2.4. End points

1- To evaluate BUN changes with respect to WRF occurrence during hospitalization.
2- To study associations of isolated BUN increase, WRF and their combination with outcome
3- To analyze the relationship existing among BUN, WRF and relief from congestion.

2.5. Follow-up

Patients were followed for 180 days after discharge with clinical visits and telephone contacts. The primary outcome of interest was a composite of all-cause mortality (ACM) or HF hospitalization (HFH).

2.6. Statistical analysis

Categorical data are presented as number and percentages; normally distributed continuous data as mean ± SD and non-normally distributed continuous variables as median and interquartile range. Patients with AHF were grouped by phenotypes according to WRF, BUN increase ≥ or <20% or by effective, or not, decongestion during hospitalization. One-way ANOVA and Kruskal-Wallis tests were used to compare continuous variables between groups depending on the normality of the distribution, and the chi-squared test was used for categorical variables.

Different multivariable Cox proportional hazard regression models were used to investigate the relationship between WRF, BUN and outcome. Multivariable models were adjusted for clinical variables of interest (age, gender, hypertension, diabetes, dyslipidemia, coronary artery disease, CKD and smoking habits) chosen prospectively *a priori*. Kaplan-Meier curves with the log-rank statistic were used to illustrate outcome. All analyses were performed using SPSS 20.0 for Windows (SPSS Inc., Chicago IL). A 2-sided *P* value <0.05 was considered statistically significant.

3. Results

3.1. Patient characteristics

Of the 267 patients with AHF enrolled, 12 were excluded because of end-stage renal failure and 8 were lost to follow-up, leaving a final cohort of 247 patients. Median age was 83[76–88] years and 123 (49%) were male; CKD at admission was prevalent in 101 patients (41%), median creatinine was 1.30[1.00–1.69] mg/dl, BUN 66[47–91] mg/dl and BNP 749[429–1150] pg/mL (Table 1). During hospitalization, 59 (24%) patients developed WRF and 107 (43%) an increase in BUN ≥20%. According to development of BUN increase and/or WRF patients were divided in 4 groups: 37 patients (15%) had both BUN increase and WRF (Group A), 70 (28%) had isolated BUN increase (Group B), 22 (9%) had

Table 1
Baseline characteristics.

All patients	
Age (years)	83[76–88]
Gender (n)	
Female	124
Male	123
Admission creatinine (mg/dl)	1.30[1.00–1.69]
Creatinine at discharge (mg/dl)	1.40[1.00–1.74]
eGFR at admission (ml/min/1.73 m ²)	49[37–65]
eGFR at discharge (ml/min/1.73 m ²)	47[33–66]
Admission BUN (mg/dl)	66[47–91]
BUN at discharge (mg/dl)	74[49–104]
Admission BNP (pg/ml)	749[429–1150]
BNP at discharge (pg/ml)	441[155–781]
Ejection fraction (%)	35[25–43]
Risk factors %/(n)	
Chronic kidney disease	41/(101)
Diabetes mellitus	36/(90)
Hypertension	37/(92)
Dyslipidemia	35/(88)
Smokers	23/(57)
Ischemic heart disease	41/(101)
Atrial fibrillation	28/(70)
WRF %/(n)	24/(59)
BUN increase ≥20%/(n)	43/(107)
BNP decrease ≥30%/(n)	66/(165)
Medication at admission %/(n)	
Beta-blockers	66/(164)
Aldosterone antagonists	19/(48)
Ace inhibitors	73/(180)
Angiotensin receptors blockers	27/(67)
Nitrates	39/(95)
Digoxin	10/(37)
Statins	52/(129)
Thiazides	6/(14)
Loop diuretics	94/(233)

Abbreviations: BNP, B-type natriuretic peptide; BUN, Blood urea nitrogen; eGFR, Estimated glomerular filtration rate.

isolated WRF (Group C) and 118 (48%) patients had neither WRF nor BUN increase (Group D).

Patients who developed both WRF and BUN increase and those with isolated WRF had the highest levels of BNP at admission, and a lower left ventricular ejection fraction (LVEF) compared to other two groups (Supplementary Table 1).

3.2. Outcome

During 180 days of follow-up, 136 (55%) patients died or were re-hospitalised for AHF. In univariable analysis, both WRF and BUN increase were associated with poor prognosis. An increase in BUN ≥ 20% was independently associated with an increased risk of ACM or HFH, regardless of incident WRF (U-HR 1.64 [1.09–2.45], *p* = 0.017; M-HR 1.71 [1.14–2.59], *p* = 0.01); incident WRF was not an independent predictor of outcome if BUN did not increase (U-HR 1.60 [0.87–2.95], *p* = 0.13; M-HR 1.66 [0.88–3.10], *p* = 0.12.). Those with both WRF and BUN increase had the worst outcome (U-HR 2.38 [1.50–3.77], *p* < 0.001; M-HR 2.19 [1.35–3.54], *p* = 0.002.). (Table 2 and Fig. 1).

3.3. Renal function trajectories and congestion

To evaluate the impact of congestion, we divided our patients according to the BUN changes and persistence or not of congestion at discharge. Univariate analysis showed that BUN increase ≥20% at discharge was related to poor outcome either without effective decongestion (HR = 2.58 [1.51–4.40]; *p* < 0.001) and with effective decongestion (HR = 1.91 [1.11–3.29]; *p* = 0.02). After adjustment for potential confounders, multivariable analysis confirmed the previous findings (HR = 2.70 [1.57–4.63]; *p* < 0.001. HR = 1.81 [1.04–3.14]; *p* = 0.035) (Supplementary Table 2 and Fig. 2).

Table 2
Univariate and multivariable analysis.

Rehospitalization or death						
Variable	Univariable analysis		Multivariable analysis ^a			
	HR (95% CI)	p-value	HR (95% CI)	p-value	HR (95% CI)	p-value
BUN increase $\geq 20\%$ and WRF	2.38 (1.50–3.77)	<0.001	–	–	2.19 (1.35–3.54)	0.002
BUN increase $\geq 20\%$ without WRF	1.64 (1.09–2.45)	0.017	–	–	1.71 (1.14–2.59)	0.010
BUN increase $< 20\%$ with WRF	1.60 (0.87–2.95)	0.13	–	–	1.66 (0.88–3.10)	0.12
BUN increase $< 20\%$ without WRF	Ref	–	–	–	Ref	–
Effective decongestion (yes vs no)	0.76 (0.54–1.08)	0.12	–	–	–	–
CKD (yes vs no)	1.33 (0.95–1.87)	0.09	1.24 (0.85–1.79)	0.27	1.25 (0.89–1.82)	0.24
BUN increase $\geq 20\%$ (vs $< 20\%$)	1.72 (1.23–2.41)	0.002	1.60 (1.13–2.27)	0.009	–	–
WRF (yes vs no)	1.69 (1.17–2.44)	0.005	1.41 (0.95–2.10)	0.09	–	–
BNP decrease $\geq 30\%$	1.04 (0.73–1.49)	0.82	–	–	–	–

Abbreviations: B-type Natriuretic Peptide (BNP); Blood Urea Nitrogen (BUN); Coronary heart disease (CHD); Chronic Kidney Disease (CKD); Confidence Interval (CI); Hazard Ratio (HR); Worsening renal function (WRF). Two separate multivariable analyses are shown: in the first one (middle column) both BUN increase and WRF were simultaneously entered in the model, in the second (right column) we entered in the model the four patients' phenotypes (according to BUN increase (\geq or $< 20\%$) and WRF).

^a Models were adjusted for clinical variables of interest chosen prospectively (age, gender, and hypertension, diabetes, dyslipidemia, CHD, CKD and smoking habits).

We performed a further analysis evaluating the associations of incident WRF, congestion and outcome, and we observed that WRF was related to poor prognosis only if an effective decongestion was not achieved (Univariate HR = 2.14 [1.31–3.51]; $p = 0.001$. Multivariable HR = 2.20 [1.32–3.68]; $p = 0.003$) Supplementary Table 2 and Supplementary Fig. 1).

4. Discussion

Our study, conducted in a daily life clinical scenario, shows that WRF is common in patients treated for AHF, but an increase in BUN $\geq 20\%$ from baseline is even more common. Importantly, we found that an increase in BUN $\geq 20\%$ during admission is a powerful predictor of adverse outcome; WRF has a significant prognostic impact only if associated

with an increase in BUN or with the inability to control clinical congestion. Interestingly, our results suggest that caution is needed when relief from congestion causes a disproportionate increase in BUN.

The bidirectional relation existing between heart and kidneys is well known, however the prevalence, and incidence, of renal dysfunction in patients with chronic and AHF is poorly reported in clinical trials and observational studies. Studies rarely provide a definition of renal dysfunction, and different specific phenotype of renal dysfunction might be contemplated, with different impact on clinical outcomes [23]. Importantly, no universal agreement exists to what blood marker has to be used to define, and monitor, renal function. Our findings demonstrated that patients experiencing BUN increase have also an higher prevalence of unfavorable condition such as CAD, atrial fibrillation and advanced CKD stage that could potentially impair outcome, although




Fig. 1. Kaplan Meier curves showing adverse events occurrence according BUN and WRF groups.

multivariable analysis showed that BUN is independently related to adverse event.

Otherwise, some might argue that BUN is not a specific renal marker, as it might reflect an increased neurohormonal activity and the effects of vasopressin (AVP) enhancing reabsorption of urea at the distal tubule [16]. Acute arterial underfilling and overdiuresis, occurring during aggressive treatment with diuretics, could further activate the sympathetic and AVP systems, and subsequently increase BUN levels. Importantly, circulating BUN is also elevated secondary to an increased protein catabolism, as it might happen during cachexia, which could further contribute to an adverse outcome.

Our results appear confirmatory of previous multicenter trials conducted in the acute and chronic heart failure setting: in the OPTIME trial, a significant increase (>25%) in BUN was frequent (40%) during hospitalizations for HF, and was strongly related to increased mortality [24]. Similarly, in the ACTIV in CHF trial, BUN, but not creatinine, was an independent predictor of morbidity and mortality [25]. Moreover, the RELAX trial suggested that WRF was not a powerful predictor of poor outcome [26]. In line with the current study, Kajimoto and colleagues studied >4000 patients with AHF enrolled in a national registry in Japan, and showed that a reduced eGFR at discharge (<45 ml/min per 1.73 m²) was associated with a significantly higher risk of all-cause mortality only if there was a concomitant elevation in BUN (≥25 mg/dl) [27]. Elevated levels of BUN are also powerful predictors of adverse outcome in ambulatory patients with heart failure [28]. Worsening congestion is one of the key reasons for admission for patients with heart failure, and the failure of its treatment it is one of the main drivers of outcome. Metra et al. showed that WRF during AHF hospitalizations is associated with increased morbidity and mortality only when clinical congestion persists at discharge, suggesting that effective decongestion might be more important than changes in renal function [29]. We expanded this data, and we identified a population of patients with AHF in whom the risk of adverse outcome remains high even when clinical congestion is effectively relieved but at the expenses of a substantial rise in BUN levels. A proof of these concepts, appears to be

confirmed by two recent *post hoc* analysis from PROTECT and RELAX-AHF trials examining diuretic response during hospitalization phase [26,30,31]. Both studies showed a strict relation among poor diuretic response, renal dysfunction and congestion. In the RELAX-AHF trial, WRF was not a predictor of poor outcome, conversely BUN increase was strictly related to reduced diuretic response confirming the hypothesis that the primarily driver of Cardio-Renal Syndrome indwells at tubular level [26]. Higher levels of BUN were also one of the strongest predictors of reduced diuretic response in the PROTECT trial, supporting the concept that sustained activation of the neuro-hormonal system might increase urea reabsorption in the kidneys, which might precede a detectable deterioration in renal function due to hypoperfusion [31]. Finally, creatinine and eGFR are the two biomarkers currently involved in WRF diagnosing, unfortunately both parameters are not useful to precociously recognize WRF. In addition, they are not able to identify the causes of the underlying sudden renal deterioration (i.e tubular, glomerular, or collector duct) [23]. Most of patients with reduced natriuretic and diuretic response experienced some degree of tubular damage and renal sodium avidity. Interestingly, patients with CKD displayed a better diuretic response compared to patients with preserved renal function [32,33].

This peculiar finding confirms that previously described by Testani and colleagues in a population of stable patients with heart failure and reduced LVEF [34]. They found that use of high doses of loop diuretics is only associated with mortality in patients with elevated BUN (>21.0 mg/dl), which might reflect a significant activation of the neuro-endocrine system.

In patients with acute heart failure, cardio-renal dysfunction and neuro-hormonal activation are relevant features together with systemic congestion. Although loop diuretic are the main drug to reduce congestion, they could potentially contribute to activate neuro-hormonal with both increase in sodium concentration in the macula densa and afferent arterial vasoconstriction. An optional strategy balancing volume status with modulation of sympathetic and RAA tone could lead to a better diuretic dose optimization [35].




Fig. 2. Kaplan Meier curves showing adverse events occurrence according to BUN increase and decongestion.

5. Limitations

This is a relatively small, single center, retrospective, observational study, with limited power. It was conducted in a tertiary hospital where patients admitted with AHF are usually older and with more comorbidities than those enrolled in clinical trials and recent registries, which might explain the high morbidity and mortality during follow-up [36]. Also, only consenting patients considered suitable for the Diur-HF trial were screened and enrolled in this study, which introduces further selection bias. In addition, treating physicians were not blinded to clinical congestion, renal function or BUN modifications occurred during hospitalization and different therapeutic choices might have influenced results.

Clinical assessment of congestion is highly subjective and it is frequent to observe disagreement among colleagues assessing congestion, particularly when this is not obvious; importantly, a comprehensive clinical evaluation might also take time and all these factors might have influenced how congestion was clinically assessed.

Moreover, there is no specific algorithm to assess or grade congestion, and there is no guidance for an objective use of loop diuretics. The use of ultrasound, for instance by measuring the inferior vena cava or jugular vein diameters, or other non-invasive technologies such as spectroscopy or bio-impedance, could provide more robust methods to quantify congestion and its responses to administration of diuretics [37,38]. Importantly, we did not serially assess weight changes and we did not measure invasively central venous pressure, right atrial pressure and left ventricle filling pressure, all of which would have provided further insight on the complex interactions between WRF, BUN and congestion.

For all these reasons, our findings should be interpreted with caution and need to be confirmed in larger, less selective, prospective cohorts.

6. Conclusions

Blood urea nitrogen (BUN) increase $\geq 20\%$ during hospitalization for AHF predicts a higher rate of adverse events after discharge, regardless of changes in renal function or clinical congestion. Conversely, isolated WRF did not demonstrate any association with adverse outcome. If our findings will be confirmed in larger sample size, the role of WRF during hospitalization should be reviewed taking into the account BUN variability. Whether combining measurements of BUN levels with other ultrasound and biochemical methods quantifying congestion might be useful to improve outcomes, requires further investigations.

Supplementary data to this article can be found online at <https://doi.org/10.1016/j.ijcard.2018.11.108>.

Conflict of interests

None declared.

Funding resources

None.

References

- [1] P. Ponikowski, A.A. Voors, S.D. Anker, H. Bueno, J.G. Cleland, A.J. Coats, V. Falk, J.R. González-Juanatey, V.P. Harjola, E.A. Jankowska, M. Jessup, C. Linde, P. Nihoyannopoulos, J.T. Parissis, B. Pieske, J.P. Riley, G.M. Rosano, L.M. Ruilope, F. Ruschitzka, F.H. Rutten, P. van der Meer, Authors/Task Force Members; Document Reviewers., ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure of the European Society of Cardiology (ESC) developed with the special contribution of the Heart Failure Association (HFA) of the ESC, *Eur. Heart J.* 37 (2016) 2129–2200.
- [2] K.F. Adams Jr., G.C. Fonarow, C.L. Emerman, T.H. Le Jemtel, M.R. Costanzo, W.T. Abraham, R.L. Berkowitz, M. Galvao, D.P. Horton, ADHERE Scientific Advisory Committee and Investigators. Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE), *Am. Heart J.* 149 (2005) 209–216.
- [3] W. Ouwerkerk, A.A. Voors, A.H. Zwinderman, Factors influencing the predictive power of models for predicting mortality and/or heart-failure hospitalization in patients with heart failure, *JACC Heart Fail.* 2 (2014) 429–436.
- [4] D. Mozaffarian, S.D. Anker, I. Anand, D.T. Linker, M.D. Sullivan, J.G.F. Cleland, P.E. Carson, A.P. Maggioni, D.L. Mann, B. Pitt, P.A. Poole-Wilson, W.C. Levy, Prediction of mode of death in heart failure: the Seattle Heart Failure Model, *Circulation* 116 (2007) 392–398.
- [5] J.G. Cleland, V. Carubelli, T. Castiello, A. Yassin, P. Pellicori, R. Antony, Renal dysfunction in acute and chronic heart failure: prevalence, incidence and prognosis, *Heart Fail. Rev.* 17 (2012) 133–149.
- [6] J.T. Heywood, G.C. Fonarow, High prevalence of renal dysfunction and its impact on outcome in 118,465 patients hospitalized with acute decompensated heart failure: a report from the ADHERE Database, *J. Card. Fail.* 13 (2007) 422–430.
- [7] W.T. Abraham, G.C. Fonarow, N.M. Albert, et al., OPTIMIZE-HF Investigators and Coordinators, Predictors of in-hospital mortality in patients hospitalized for heart failure: insights from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF), *J. Am. Coll. Cardiol.* 52 (2008) 347–356.
- [8] K. Damman, M.A. Valente, A.A. Voors, C.M. O'Connor, D.J. van Veldhuisen, H.L. Hillege, Renal impairment, worsening renal function, and outcome in patients with heart failure: an updated meta-analysis, *Eur. Heart J.* 35 (2014) 455–469.
- [9] K. Damman, T. Jaarsma, A.A. Voors, G. Navis, H.L. Hillege, D.J. van Veldhuisen, COACH investigators, Both in- and out-hospital worsening of renal function predict outcome in patients with heart failure: results from the Coordinating Study Evaluating Outcome of Advising and Counseling in Heart Failure (COACH), *Eur. J. Heart Fail.* 11 (2009) 847–854.
- [10] E. Raichlin, N.A. Haglund, I. Dumitru, E.R. Lyden, M.D. Johnston, J.M. Mack, J.R. Windle, B.D. Lowes, Worsening renal function in patients with acute decompensated heart failure treated with ultrafiltration: predictors and outcomes, *J. Card. Fail.* 20 (2014) 376.e25–376.e32.
- [11] R.D. Kociol, M.A. Greiner, B.G. Hammill, H. Phatak, G.C. Fonarow, L.H. Curtis, A.F. Hernandez, Long-term outcomes of Medicare beneficiaries with worsening renal function during hospitalization for heart failure, *Am. J. Cardiol.* 105 (2010) 1786–1793.
- [12] J.M. Testani, J. Chen, B.D. McCauley, S.E. Kimmel, R.P. Shannon, Potential effects of aggressive decongestion during the treatment of decompensated heart failure on renal function and survival, *Circulation* 122 (2010) 265–272.
- [13] D.E. Lanfear, E.L. Peterson, J. Campbell, H. Phatak, D. Wu, K. Wells, J.A. Spertus, L.K. Williams, Relation of worsened renal function during hospitalization for heart failure to long-term outcomes and rehospitalization, *Am. J. Cardiol.* 107 (2011) 74–78.
- [14] S. Ather, C. Bavishi, M.D. McCauley, A. Dhaliwal, A. Deswal, S. Johnson, W. Chan, D. Aguilar, A.M. Pritchett, K. Ramasubbu, X.H. Wehrens, B. Bozkurt, Worsening renal function is not associated with response to treatment in acute heart failure, *Int. J. Cardiol.* 167 (2013) 1912–1917.
- [15] R.W. Schrier, Blood urea nitrogen and serum creatinine: not married in heart failure, *Circ. Heart Fail.* 1 (2008) 2–5.
- [16] A. Kazory, Emergence of blood urea nitrogen as a biomarker of neurohormonal activation in heart failure, *Am. J. Cardiol.* 106 (2010) 694–700.
- [17] A. Palazzuoli, G. Ruocco, G. Vescovo, R. Valle, S. Di Somma, R. Nuti, Rationale and study design of intravenous loop diuretic administration in acute heart failure: DIUR-AHF, *ESC Heart Fail.* 4 (2017) 479–486.
- [18] M. Gheorghiadu, F. Follath, P. Ponikowski, J.H. Barsuk, J.E. Blair, J.G. Cleland, K. Dickstein, M.H. Drazner, G.C. Fonarow, T. Jaarsma, G. Jondeau, J.L. Sendon, A. Mebazaa, M. Metra, M. Nieminen, P.S. Pang, P. Seferovic, L.W. Stevenson, D.J. van Veldhuisen, F. Zannad, S.D. Anker, A. Rhodes, McMurray JJ, G. Filippatos, European Society of Cardiology, European Society of Intensive Care Medicine, Assessing and grading congestion in acute heart failure: a scientific statement from the acute heart failure committee of the heart failure association of the European Society of Cardiology and endorsed by the European Society of Intensive Care Medicine, *Eur. J. Heart Fail.* 12 (2010) 423–433.
- [19] A.S. Levey, J. Coresh, T. Greene, et al., Chronic Kidney Disease Epidemiology Collaboration, Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate, *Ann. Intern. Med.* 145 (2006) 247–254.
- [20] Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group, KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease, *Kidney Int. Suppl.* 3 (2013) 1–150.
- [21] K. Damman, W.H. Tang, J.M. Testani, J.J. McMurray, Terminology and definition of changes renal function in heart failure, *Eur. Heart J.* 35 (2014) 3413–3416.
- [22] G. Ruocco, M. Pellegrini, C. De Gori, B. Franci, R. Nuti, A. Palazzuoli, The prognostic combined role of B-type natriuretic peptide, blood urea nitrogen and congestion signs persistence in patients with acute heart failure, *J. Cardiovasc. Med. (Hagerstown)* 17 (2016) 818–827.
- [23] A. Palazzuoli, C. Lombardi, G. Ruocco, M. Padeletti, R. Nuti, M. Metra, C. Ronco, Chronic kidney disease and worsening renal function in acute heart failure: different phenotypes with similar prognostic impact? *Eur. Heart J. Acute Cardiovasc. Care* 5 (2015) 534–548.
- [24] L. Klein, B.M. Massie, J.D. Leimberger, et al., Admission or changes in renal function during hospitalization for worsening heart failure predict post discharge survival. Results from the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF), *Circ. Heart Fail.* 1 (2008) 25–33.
- [25] G. Filippatos, J. Rossi, D.M. Lloyd-Jones, W.G. Stough, J. Ouyang, D.D. Shin, C. O'Connor, K.F. Adams, C. Orlandi, M. Gheorghiadu, Prognostic value of blood urea

- nitrogen in patients hospitalized with worsening heart failure: insights from the Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Chronic Heart Failure (ACTIV in CHF) study, *J. Card. Fail.* 13 (2007) 360–364.
- [26] A.A. Voors, B.A. Davison, J.R. Teerlink, G.M. Felker, G. Cotter, G. Filippatos, B.H. Greenberg, P.S. Pang, B. Levin, T.A. Hua, T. Severin, P. Ponikowski, M. Metra, RELAX-AHF Investigators. Diuretic response in patients with acute decompensated heart failure: characteristics and clinical outcome—an analysis from RELAX-AHF, *Eur J Heart Fail.* 16 (2014) 1230–1240.
- [27] K. Kajimoto, N. Sato, T. Takano, ATTEND investigators, eGFR and outcomes in patients with acute decompensated heart failure with or without elevated BUN, *Clin. J. Am. Soc. Nephrol.* 11 (2016) 405–412, <https://doi.org/10.2215/CJN.08210815>.
- [28] J.M. Testani, S.G. Coca, R.P. Shannon, S.E. Kimmel, T.P. Cappola, Influence of renal dysfunction phenotype on mortality in the setting of cardiac dysfunction: analysis of three randomized controlled trials, *Eur. J. Heart Fail.* 13 (2011) 1224–1230.
- [29] M. Metra, B. Davison, L. Bettari, H. Sun, C. Edwards, V. Lazzarini, B. Piovanelli, V. Carubelli, S. Bugatti, C. Lombardi, G. Cotter, Cas L. Dei, Is worsening renal function an ominous prognostic sign in patients with acute heart failure? The role of congestion and its interaction with renal function, *Circ. Heart Fail.* 5 (2012) 54–62.
- [30] C.M. O'Connor, R.J. Mentz, G. Cotter, M. Metra, J.G. Cleland, B.A. Davison, M.M. Givertz, G.A. Mansoor, P. Ponikowski, J.R. Teerlink, A.A. Voors, M. Fiuzat, D. Wojdyla, K. Chiswell, B.M. Massie, The PROTECT in-hospital risk model: 7-day outcome in patients hospitalized with acute heart failure and renal dysfunction, *Eur. J. Heart Fail.* 14 (2012) 605–612.
- [31] M.A. Valente, A.A. Voors, K. Damman, D.J. Van Veldhuisen, B.M. Massie, C.M. O'Connor, M. Metra, P. Ponikowski, J.R. Teerlink, G. Cotter, B. Davison, J.G. Cleland, M.M. Givertz, D.M. Bloomfield, M. Fiuzat, H.C. Dittrich, H.L. Hillege, Diuretic response in acute heart failure: clinical characteristics and prognostic significance, *Eur. Heart J.* 35 (2014) 1284–1293.
- [32] J.M. Ter Maaten, V.S. Rao, J.S. Hanberg, F. Perry Wilson, L. Bellumkonda, M. Assefa, J. Sam Broughton, J. D'Ambrosi, W.H. Wilson Tang, K. Damman, A.A. Voors, D.H. Ellison, J.M. Testani, Renal tubular resistance is the primary driver for loop diuretic resistance in acute heart failure, *Eur. J. Heart Fail.* 19 (2017) 1014–1022.
- [33] W. Mullens, F.H. Verbrugge, P. Nijst, W.H.W. Tang, Renal sodium avidity in heart failure: from pathophysiology to treatment strategies, *Eur. Heart J.* 38 (2017) 1872–1882.
- [34] J.M. Testani, T.P. Cappola, C.M. Brensinger, R.P. Shannon, S.E. Kimmel, Interaction between loop diuretic-associated mortality and blood urea nitrogen concentration in chronic heart failure, *J. Am. Coll. Cardiol.* 58 (2011) 375–382.
- [35] S.R. Goldsmith, B.A. Bart, I.L. Pin, Neurohormonal imbalance: a neglected problem—and potential therapeutic target—in acute heart failure, *Curr. Probl. Cardiol.* 43 (2018 Jul) 294–304, <https://doi.org/10.1016/j.cpcardiol.2017.12.002>.
- [36] M.G. Crespo-Leiro, S.D. Anker, A.P. Maggioni, A.J. Coats, G. Filippatos, F. Ruschitzka, R. Ferrari, M.F. Piepoli, J.F. Delgado Jimenez, M. Metra, C. Fonseca, J. Hradec, O. Amir, D. Logeart, U. Dahlström, B. Merkely, J. Drozd, E. Goncalvesova, M. Hassanein, O. Chioncel, M. Lainscak, P.M. Seferovic, D. Tousoulis, A. Kavaliuniene, F. Fruhwald, E. Fazlibegovic, A. Temizhan, P. Gatzov, A. Erglis, C. Laroche, A. Mebazaa, Heart Failure Association (HFA) of the European Society of Cardiology (ESC), European society of cardiology heart failure long-term registry (ESC-HF-LT): 1-year follow-up outcomes and differences across regions, *Eur. J. Heart Fail.* 18 (2016) 613–625.
- [37] P. Pellicori, A. Kallvikbacka-Bennett, R. Dierckx, J. Zhang, P. Putzu, J. Cuthbert, V. Boyalla, A. Shoaib, A.L. Clark, J.G. Cleland, Prognostic significance of ultrasound-assessed jugular vein distensibility in heart failure, *Heart* 101 (2015) 1149–1158.
- [38] P. Pellicori, A.L. Clark, A. Kallvikbacka-Bennett, J. Zhang, A. Urbinati, L. Monzo, R. Dierckx, S.D. Anker, J.G.F. Cleland, Non-invasive measurement of right atrial pressure by near-infrared spectroscopy: preliminary experience. A report from the SICA-HF study, *Eur. J. Heart Fail.* 19 (2017) 883–892.